FX006: Clinical Trials

12 trials of FX006, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 2 terminated. 12 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 212Completed 10, Terminated 2

Follow FX006: new trials by email Literature Review of FX006 trials Research Report on FX006

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess the Safety and Efficacy of FX006 Administered to Patients With Greater Trochanteric Bursitis
FX006 - Trochanteric Bursitis
Phase 2CompletedThe University of Texas Health Science Center, Houston222020-08-122024-01-02
Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis
FX006, Normal Saline - Osteoarthritis of the Shoulder, Adhesive Capsulitis
Phase 2TerminatedPacira Pharmaceuticals, Inc192019-11-072024-01-24
Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip
FX006 32 mg - Osteoarthritis, Hip
Phase 2CompletedPacira Pharmaceuticals, Inc162019-07-302024-01-24
Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip
FX006 32 mg, TAcs 40 mg - Osteoarthritis of the Shoulder, Osteoarthritis of the Hip
Phase 2CompletedPacira Pharmaceuticals, Inc552017-12-182024-01-24
Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA
FX006 32 mg, TAcs 40 mg - Bilateral Knee Osteoarthritis
Phase 2CompletedPacira Pharmaceuticals, Inc242017-12-062024-01-24
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
FX006 32 mg, TCA IR 40 mg - Osteoarthritis of the Knee, Type 2 Diabetes Mellitus
Phase 2CompletedPacira Pharmaceuticals, Inc332016-04-012024-01-24
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
FX006 32 mg, TCA IR 40 - Osteoarthritis of the Knee
Phase 2CompletedPacira Pharmaceuticals, Inc812015-11-012024-01-24
Proof of Concept Study Comparing FX006 to KenalogĀ®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee
FX006 32 mg, TCA IR 40 mg - Post-traumatic Osteoarthritis of the Knee
Phase 2TerminatedPacira Pharmaceuticals, Inc62015-02-012024-01-24
Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee
FX006 32 mg, Placebo, FX006 16 mg - Osteoarthritis of the Knee
Phase 2CompletedPacira Pharmaceuticals, Inc3102014-04-012024-01-24
Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
FX006 10 mg, FX006 40 mg, TCA IR 40 mg - Osteoarthritis of the Knee
Phase 2CompletedPacira Pharmaceuticals, Inc502013-11-012024-01-24
Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee
FX006 10 mg, FX006 40 mg, FX006 60 mg - Osteoarthritis of the Knee
Phase 2CompletedPacira Pharmaceuticals, Inc242012-07-012024-01-24
Study of FX006 in Patients With Osteoarthritis of the Knee
FX006, TCA IR - Osteoarthritis of the Knee
Phase 2CompletedPacira Pharmaceuticals, Inc2292012-06-012024-01-24

Conditions studied

Osteoarthritis (11)  ·  Pain (8)  ·  Osteoarthritis, Knee (6)  ·  Osteoarthritis, Hip (2)  ·  Bursitis (1)  ·  Diabetes Mellitus (1)  ·  Diabetes Mellitus, Type 2 (1)

Sponsors

Pacira Pharmaceuticals, Inc (11)  ·  The University of Texas Health Science Center, Houston (1)

Countries

United States (11)  ·  Australia (2)  ·  Canada (2)

Top investigators

Neil Bodick, MD (6)  ·  Scott Kelley, MD (3)  ·  Neil Bodick, MD, PhD (1)  ·  Pritish Bawa, MD (1)  ·  Scott Kelley (1)

Results publications

PMID 29088579, PMID 30203101, PMID 31662801, PMID 34350546, PMID 35258839